Damora Therapeutics (DMRA) Times Interest Earned (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Times Interest Earned came in at -$2.7 in Q1 2026, up 90.87% YoY from -$1.41 in Q1 2025, and up 99.99% on a QoQ basis from -$40339.2 in Q4 2025.
Damora Therapeutics (DMRA) Times Interest Earned (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Times Interest Earned data on file, last reported at -$2.7 in Q1 2026.
- Quarterly Times Interest Earned rose 90.87% year-over-year to -$2.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.93 (up 90.36% YoY) and the FY2025 annual result came in at -$2.8, down 744.29% from the prior year.
- Times Interest Earned improved to -$2.7 in Q1 2026, from -$40339.2 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$2.7 in Q1 2026 to a low of -$40339.2 in Q4 2025.
- A 5-year average of -$2443.7 and a median of -$70.93 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 97.6% — and 2025, when it tumbled 18643.93%.
- Tracing DMRA's Times Interest Earned over 5 years: stood at -$87.26 in 2022, then soared by 55.29% to -$39.01 in 2023, then sank by 451.66% to -$215.21 in 2024, then plunged by 18643.93% to -$40339.2 in 2025, then jumped by 99.99% to -$2.7 in 2026.
- The last three Times Interest Earned figures came in at -$2.7 (Q1 2026), -$40339.2 (Q4 2025), and -$157.8 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -3.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.16 |
| Mar 31, 2026 | -2.70 |
| Dec 31, 2025 | -40,339.20 |
| Sep 30, 2025 | -157.80 |
| Jun 30, 2025 | -38.44 |
| Mar 31, 2025 | -29.53 |
| Dec 31, 2024 | -215.21 |
| Sep 30, 2024 | -76.80 |
| Jun 30, 2024 | -116.19 |
| Mar 31, 2024 | -62.40 |
| Dec 31, 2023 | -39.01 |
| Sep 30, 2023 | -70.93 |
| Jun 30, 2023 | -3.43 |
| Mar 31, 2023 | -9.43 |
| Dec 31, 2022 | -87.26 |
| Sep 30, 2022 | -101.66 |
| Jun 30, 2022 | -142.68 |
| Mar 31, 2022 | -49.78 |
| Dec 31, 2021 | -122.44 |
| Sep 30, 2021 | -6.28 |